PANDAS and PANS in Children: A Father's Guide to Recognition, Diagnosis, and Treatment
by Fatherhood United | www.fatherhoodunited.com
The Overnight Transformation
Every father remembers the baseline of his child. You know their typical laughter, their bedtime routines, their favorite foods, and how they handle everyday frustrations. For most parents, developmental shifts occur gradually over months or years. However, fathers of children affected by Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) or Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) describe a terrifyingly different reality. They can often pinpoint the exact date, and sometimes even the exact hour, when their child seemingly fell off a psychological cliff.
A previously calm, affectionate, and thriving child may wake up transformed. Overnight, severe contamination fears, intrusive thoughts, screaming fits, complex motor tics, bedwetting, and sudden refusal to eat can overwhelm the household. A father who was playing catch with his son on Saturday might find himself on Monday desperately reassuring a terrified child experiencing acute panic, or watching his daughter wash her hands until her skin bleeds.
This sudden, fulminant onset is the hallmark of PANDAS and PANS in children. Unfortunately, because these conditions sit at the complex intersection of pediatric neurology, immunology, and child psychiatry, fathers frequently encounter clinical skepticism, misdiagnoses, and conflicting medical advice. Many parents are told that their child is simply showing behavioral defiance, experiencing stress, or entering a strange developmental phase. Others face devastating accusations of improper parenting or exaggerating symptoms.

This article for Fatherhood United provides a grounded, evidence-based roadmap for fathers navigating PANDAS and PANS in children. By examining the biological mechanisms, diagnostic criteria, evidence-based treatments, and practical advocacy strategies, this guide aims to equip fathers with the knowledge needed to advocate effectively for their children and restore peace to their families.
Deconstructing PANDAS and PANS in Children: Definitions and Diagnostic Criteria

To advocate effectively for a child, fathers must first understand the clinical definitions and diagnostic boundaries surrounding these conditions. While PANDAS and PANS share an identical core clinical phenotype of sudden-onset neuropsychiatric deterioration, they differ in their recognized triggers, age requirements, and diagnostic criteria.
The Historical Origin of PANDAS
The clinical concept of PANDAS was first defined in 1998 by Dr. Susan Swedo and her research team at the National Institute of Mental Health (Swedo et al., 1998). Dr. Swedo observed a unique subgroup of pediatric patients who presented with explosive obsessive-compulsive disorder (OCD) or tic disorders shortly after a Group A β-hemolytic Streptococcal (GABHS) infection, such as strep throat or scarlet fever. Building on historical models of Sydenham chorea, a neurological manifestation of acute rheumatic fever caused by post-streptococcal autoimmunity, Swedo proposed five specific working criteria for PANDAS:
Presence of OCD and/or a tic disorder: The primary clinical presentation must feature diagnostic-level OCD, motor or phonic tics, or both.
Prepubertal symptom onset: Symptoms must first become evident between 3 years of age and the onset of puberty.
Acute onset and episodic course: Symptom onset is explosive, followed by a relapsing-remitting trajectory characterized by dramatic flares and partial or complete remissions.
Temporal relationship with Group A Streptococcus: Exacerbations must be temporally linked to documented GABHS infections, confirmed via throat cultures, rapid antigen tests, or rising serological titers.
Association with neurological abnormalities: During symptom flares, children display adventitious movements, motor hyperactivity, choreiform movements, or physical restlessness.
The Evolution to PANS
While the PANDAS construct represented a major breakthrough, clinicians soon recognized that an identical, sudden-onset neuropsychiatric presentation could be triggered by non-streptococcal pathogens or environmental stressors. In response, the PANS Consensus Conferences of 2012 to 2015 formally established the broader umbrella diagnosis of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) (Swedo et al., 2012; Chang et al., 2015; Frankovich et al., 2015).
PANS broadened the clinical framework beyond streptococcal disease while refining the core criteria to focus on sudden-onset OCD or severe eating restrictions. The consensus criteria for PANS require:
Abrupt, dramatic onset of OCD or severely restricted food intake: Symptoms escalate to peak severity rapidly, typically within 24 to 48 hours. Restricted food intake often presents as Avoidant/Restrictive Food Intake Disorder (ARFID) driven by obsessional fears of choking, vomiting, or contamination.
Concurrent presence of additional neuropsychiatric symptoms: The child must exhibit acute onset of symptoms from at least two of the following seven categories:
Anxiety, especially acute separation anxiety, panic, or irrational fears
Emotional lability or depression
Irritability, aggression, or severely oppositional behaviors
Behavioral or developmental regression, such as baby talk or temper tantrums
Sudden deterioration in school performance, linked to memory deficits, inattention, or visual-spatial impairment
Sensory or motor abnormalities, including dysgraphia, hyperacusis, or tics
Somatic signs and symptoms, including sleep disruption, enuresis, or urinary frequency
Exclusion of known medical disorders: Symptoms must not be better explained by an established neurological or systemic condition, such as Sydenham chorea, Systemic Lupus Erythematosus, or Autoimmune Encephalitis.
The following comparative table summarizes the structural differences between PANDAS, PANS, and related historical terms such as Childhood Acute Neuropsychiatric Symptoms (CANS).
Feature / Criterion | Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) | Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) | Childhood Acute Neuropsychiatric Symptoms (CANS) |
Primary Mandatory Symptoms | Abrupt onset of OCD and/or motor or phonic tics (Swedo et al., 1998). | Abrupt onset of OCD or severely restricted food intake / ARFID (Swedo et al., 2012). | Abrupt onset of severe OCD or acute neuropsychiatric symptoms (Singer et al., 2012). |
Comorbid Domain Requirements | Associated with motor hyperactivity, choreiform movements, emotional lability, and anxiety. | Requires acute onset of $\ge 2$ comorbid symptoms across 7 distinct categories (Chang et al., 2015). | Requires comorbid behavioral, cognitive, or affective symptoms. |
Age Criteria | Prepubertal onset required, between age 3 and the start of puberty. | No age limit; median onset is 7 years, but post-pubertal cases occur (Aspire, 2020). | No age limit. |
Infectious / Etiological Link | Strictly associated with Group A $\beta$-hemolytic Streptococcal (GABHS) infections. | Heterogeneous: GABHS, Mycoplasma pneumoniae, Influenza, EBV, Lyme, or non-infectious stress. | Non-specific regarding infectious or autoimmune etiology. |
Clinical Course | Episodic, relapsing-remitting course tied to streptococcal exposures. | Relapsing-remitting, chronic-static, or chronic-progressive trajectories. | Relapsing-remitting or variable trajectory. |
The Biological Engine: Pathophysiology and Immunological Mechanisms

Fathers seeking to understand PANDAS and PANS in children often ask how a simple throat or respiratory infection can cause profound changes in a child's personality and behavior. The underlying biological mechanism involves post-infectious neuroinflammation and autoimmune cross-reactivity targeting the basal ganglia (Lim et al., 2026).
Molecular Mimicry and Autoantibody Generation
The primary biological model for PANDAS is rooted in molecular mimicry (Cunningham, 2019). When a child contracts a Group A Streptococcal infection, their immune system generates antibodies against bacterial cell-wall proteins, particularly M-protein epitopes. In genetically vulnerable hosts, structural homologies between these streptococcal antigens and human host tissues cause the immune system to produce cross-reactive autoantibodies (Kirvan et al., 2003).
Rather than clearing the infection exclusively, these cross-reactive antibodies circulate in the bloodstream and target neural tissues. Animal models and human translational studies demonstrate that streptococcal intranasal exposures stimulate streptococcal-specific Th17 lymphocytes in the nasal-associated lymphoid tissue. These Th17 cells migrate along olfactory neuronal pathways into the central nervous system, releasing inflammatory cytokines that compromise blood-brain barrier (BBB) integrity (Dileepan et al., 2016; Platt et al., 2020).
Basal Ganglia and Dopaminergic Circuit Disruption
Once autoantibodies cross the hyperpermeable blood-brain barrier, they selectively bind to subcortical structures within the basal ganglia, specifically the caudate nucleus, putamen, and globus pallidus (Giedd et al., 2000; Kirvan et al., 2006b). These basal ganglia structures form essential nodes within cortico-striato-thalamo-cortical (CSTC) circuits, which regulate motor control, habit formation, compulsivity, emotional inhibition, and executive function.
Recent neurobiological research has identified specific molecular targets of these circulating autoantibodies:
Dopamine D1 and D2 Receptors: Autoantibodies targeting dopamine D1 receptors (anti-D1R) and D2 receptors (anti-D2R) play a central role. Menendez and colleagues (2024) demonstrated that anti-D1R autoantibodies are selectively elevated in PANDAS and PANS patients with neuropsychiatric phenotypes (OCD and tics), signaling through G protein and $\beta$-arrestin pathways to sensitize neurons to dopamine. Conversely, anti-D2R autoantibodies predominate in Sydenham chorea movement phenotypes (Ben-Pazi et al., 2013; Menendez et al., 2024).
Lysoganglioside-GM1 and $\beta$-Tubulin: Autoantibodies reacting to lysoganglioside-GM1 and $\beta$-tubulin act as additional neuronal targets, altering cellular signaling (Kirvan et al., 2007).
CaMKII Hyperactivation: Binding of patient antibodies to neuronal cell surfaces triggers hyperactivation of Calcium/calmodulin-dependent protein kinase II (CaMKII), an enzyme that stimulates excessive dopamine release and alters signal transduction across striatal circuits (Kirvan et al., 2003; Cox et al., 2013).
Striatal Cholinergic Interneurons (CINs): Recent findings demonstrate that serum IgG from PANDAS patients selectively binds to striatal cholinergic interneurons, disrupting local striatal microcircuitry and triggering acute behavioral deficits (Xu et al., 2021, 2024).
Positron emission tomography (PET) neuroimaging using the radiopharmaceutical 11C-[R]-PK11195, which binds to activated microglia, confirmed significant neuroinflammation localized to the bilateral caudate and lentiform nuclei in children during acute PANDAS flares (Kumar et al., 2015). This neuroinflammatory cascade destabilizes CSTC circuits, leading directly to the sudden onset of compulsions, tics, emotional outbursts, and sensory distortions seen in PANDAS and PANS in children.
Recognizing the Warning Signs: Clinical Manifestations and Behavioral Shifts
For a father, recognizing the warning signs of PANDAS and PANS in children requires looking beyond standard psychiatric labels. Because the neuroinflammatory process impacts multiple basal ganglia circuits simultaneously, symptoms manifest across emotional, cognitive, motor, and somatic domains.
Primary Mandatory Symptoms
The core presentation of PANDAS and PANS in children centers on two severe behavioral disruptions:
Explosive Obsessive-Compulsive Disorder (OCD): Unlike primary pediatric OCD, which typically develops gradually over months or years, PANS-related OCD appears suddenly. Children experience terrifying intrusive thoughts regarding contamination, harm coming to parents, moral or religious obsessions, or exactness rituals. Compulsions can occupy several hours a day and include constant handwashing, repeating phrases, checking locks, touching objects symmetrically, or seeking endless reassurance (PANDAS & PANS Treatment Guidelines, 2021).
Avoidant/Restrictive Food Intake Disorder (ARFID): Sudden food refusal is often the primary presenting symptom of PANS, occurring even in the absence of obvious OCD rituals. Food restriction is frequently driven by sudden obsessional fears of choking (phagophobia), fears of vomiting (emetophobia), or contamination concerns. In severe cases, children may refuse all liquids and solids, leading to rapid weight loss, dehydration, and medical instability (Toufexis et al., 2015).
Comorbid Neurological, Cognitive, and Somatic Red Flags
Fathers should monitor for secondary symptoms that accompany the primary OCD or food restriction during an acute flare:
Dysgraphia and Fine Motor Loss: A dramatic deterioration in handwriting is one of the most specific physical markers of PANDAS and PANS in children. A child whose handwriting was clear yesterday may suddenly produce illegible scribbles, struggle with spacing, press down so hard that the pencil lead breaks, or experience severe hand tremors (International OCD Foundation, 2010).
Urinary Frequency and Nocturnal Enuresis: Children frequently develop extreme urinary urgency, needing to use the restroom every 10 to 15 minutes without evidence of a urinary tract infection. Secondary daytime wetting or new-onset bedwetting (enuresis) in a previously potty-trained child is common (Frankovich et al., 2015).
Sensory Amplification and Overload: Children often experience heightened sensitivity to sensory stimuli. They may complain bitterly that clothing seams, socks, or tags feel like sandpaper, scream at normal environmental sounds (hyperacusis), or demand that lights remain dimmed (Aspire, 2020).
Motor and Vocal Tics: Tics can range from simple motor twitches (eye blinking, shoulder shrugging, head jerking) to complex vocalizations (throat clearing, coughing, grunting, or repeating words).
Behavioral Regression and Separation Anxiety: Children may regress to developmental stages they passed years earlier. A school-aged child may exhibit baby talk, thumb-sucking, or intense separation anxiety, refusing to let a parent leave their line of sight or sleeping on the floor next to their parents' bed (Swedo et al., 2012).
Emotional Lability and Aggressive Outbursts: Neuroinflammation in subcortical circuits frequently manifests as uncharacteristic rage. Children may experience explosive tantrums, screaming fits, physical aggression, or severe emotional lability over minor triggers, leaving fathers exhausted and bewildered.
The Diagnostic Journey and Biomarker Realities
Navigating the diagnostic process for PANDAS and PANS in children can be challenging for parents. Currently, no single blood test, brain scan, or swab can definitively confirm or rule out PANS or PANDAS. Both conditions remain clinical diagnoses of exclusion (American Academy of Pediatrics, 2025; Cesaroni et al., 2026).
Interpreting Streptococcal Serology
Fathers often assume that a blood test for anti-streptolysin O (ASO) or anti-deoxyribonuclease B (anti-DNase B) titers will provide a quick answer. However, interpreting streptococcal serology requires nuanced understanding:
Serology Reflects Past Exposure, Not Current Brain Inflammation: ASO and anti-DNase B titers rise several weeks after a streptococcal infection and can remain elevated for months in healthy children (Kaplan et al., 1998). Elevated titers simply document that a child encountered Group A Streptococcus in recent months; they do not prove that streptococcus caused the neuropsychiatric symptoms (Kurlan & Kaplan, 2004; Cesaroni et al., 2026).
False Negatives in Early Infection: A negative rapid throat swab or normal serological titers at the time of acute onset do not rule out a post-streptococcal etiology, as titers may not have peaked or the streptococcal infection may reside in occult sites such as the adenoids, sinuses, or perianal region (Cooperstock et al., 2017).
The Cunningham Panel Debate
The Cunningham Panel (manufactured by Moleculera Labs) is a commercially available blood panel measuring autoantibody titers against dopamine D1R, dopamine D2R, lysoganglioside-GM1, and β-tubulin, alongside a CaMKII cell activation assay.
While manufacturer-affiliated studies report correlation between panel titers and symptom changes pre- and post-treatment (Shimasaki et al., 2020), independent blinded evaluations conducted by researchers such as Hesselmark and Bejerot (2017) demonstrated limited specificity. Healthy control children frequently met positivity criteria, while CaMKII activation levels did not reliably distinguish confirmed PANS patients from controls (Hesselmark & Bejerot, 2017; Lim et al., 2026). Consequently, major medical bodies, including the American Academy of Pediatrics (2025), recommend that the Cunningham Panel should not be used as a routine diagnostic instrument, emphasizing that biological assessment remains supportive rather than decisive.
Stepwise Differential Diagnosis
To ensure patient safety, clinicians must rule out urgent neurological and systemic medical conditions before diagnosing PANS or PANDAS (Cesaroni et al., 2026). The diagnostic evaluation should follow a structured sequence:
Rule out Urgent Conditions: Exclude Autoimmune Encephalitis (such as anti-NMDAR encephalitis), central nervous system infections, brain tumors, metabolic disorders, and acute intoxication.
Evaluate Movement Phenomenology: Distinguish tics and choreiform movements from Sydenham chorea, dystonia, or epileptic seizures.
Take a Family History: Screen for family histories of tic disorders, Tourette Syndrome, and primary OCD. High familial heritability (50% to 80%) increases the pre-test probability of a primary neurodevelopmental tic disorder (Mataix-Cols et al., 2015; Cesaroni et al., 2026).
Targeted Medical Testing: Conduct rapid throat swabs, throat cultures, ASO/anti-DNase B titers, inflammatory markers (ESR, CRP), and, where clinically indicated by neurological red flags, MRI neuroimaging, EEG, or lumbar puncture (Frontiers Review, 2021).
Evidence-Based Management: The Three-Pronged Treatment Protocol
When managing PANDAS and PANS in children, international consensus guidelines established by the PANS Research Consortium (PRC) recommend a comprehensive, three-pronged treatment strategy (Frankovich et al., 2017; Cooperstock et al., 2017; Thienemann et al., 2017). Treating only one aspect of the syndrome often yields incomplete recovery.

Prong 1: Symptom and Behavioral Management
Psychiatric and behavioral interventions provide essential functional support during acute flares and recovery (Thienemann et al., 2017):
Cognitive Behavioral Therapy (CBT) and Exposure/Response Prevention (ERP): CBT paired with ERP is the gold-standard psychotherapeutic approach for OCD and anxiety. In young children or during acute flares, therapy must be modified to match the child's cognitive capacity, focusing on gentle exposures and coaching parents to reduce family accommodation of compulsions (Calaprice et al., 2018).
Psychotropic Medications ("Start Low and Go Slow"): When psychotropic medications are needed for severe OCD, anxiety, or depression, SSRIs (such as fluoxetine or sertraline) are utilized. However, children with PANS often display heightened sensitivity to psychotropics. Clinicians must initiate treatment at ultra-low doses (25% to 50% of standard pediatric starting doses) and titrate slowly to avoid behavioral activation, akathisia, or agitation (Thienemann et al., 2017).
Alpha-2 Agonists: Medications such as guanfacine or clonidine can help manage hyperarousal, tic severity, motor restlessness, and severe sleep disruption.
Prong 2: Antimicrobial Interventions
Antimicrobial therapy aims to eliminate active or occult bacterial reservoirs, removing the primary antigenic stimulus driving autoimmunity (Cooperstock et al., 2017):
Acute Infection Treatment: For confirmed GABHS infections or acute presentations of PANDAS, a 14-day course of therapeutic antibiotics is recommended. Standard first-line options include Penicillin V, Amoxicillin, or Amoxicillin-clavulanate. Cephalosporins (such as cefdinir) or macrolides (such as azithromycin) are indicated for penicillin-allergic patients or chronic sinus infections (Cooperstock et al., 2017; PANDAS & PANS Treatment Guidelines, 2021).
Empiric Antimicrobial Trials: Consensus guidelines support a single empiric trial of antibiotics in newly diagnosed PANS cases even if rapid throat swabs are negative, in order to address occult sinus, adenoidal, or perianal bacterial infections (Cooperstock et al., 2017).
Secondary Antimicrobial Prophylaxis: In children with confirmed PANDAS who experience repeated strep-triggered relapses, continuous secondary prophylactic antibiotics (e.g., daily Penicillin V or Azithromycin) may be maintained through the academic year to prevent reinfection (Cooperstock et al., 2017; Snider et al., 2005).
Prong 3: Anti-Inflammatory and Immunomodulatory Therapies
Addressing post-infectious neuroinflammation requires anti-inflammatory or immunomodulatory therapy calibrated to disease severity (Frankovich et al., 2017):
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-the-counter or prescription NSAIDs (such as ibuprofen or naproxen) given early during a flare can reduce symptom duration and severity in mild cases (Frankovich et al., 2017; Aspire, 2020).
Oral Corticosteroids: Short bursts of oral corticosteroids (e.g., prednisone at 1 to 2 mg/kg/day for 5 days) or short corticosteroid tapers often produce dramatic improvements in mild-to-moderate initial presentations or acute flares by rapidly suppressing neuroinflammation (Frankovich et al., 2017).
Intravenous Immunoglobulin (IVIG): High-dose IVIG (1.5 to 2.0 g/kg divided over 2 days) is recommended for moderate-to-severe, relapsing-remitting, or refractory cases. IVIG delivers broad-spectrum donor antibodies that neutralize autoantibodies, modulate Fc-receptor expression, and downregulate neuroinflammation (Perlmutter et al., 1999; Frankovich et al., 2017; Kovacevic et al., 2015). Large survey data show that 89% of patients receiving IVIG report significant clinical improvement (Calaprice et al., 2018).
Therapeutic Plasma Exchange (TPE): TPE (plasmapheresis) is reserved for severe, incapacitating, or life-threatening presentations (such as severe ARFID with dehydration or extreme catatonia). TPE directly filters autoantibodies from the patient's blood, often producing rapid clinical stabilization (Perlmutter et al., 1999; Frankovich et al., 2017).
The following treatment summary matrix outlines these therapeutic options across severity tiers.
Intervention Category | Specific Modality | Clinical Role & Indications | Dosing / Protocol Concept | Safety & Monitoring Considerations |
Prong 1: Behavioral | CBT with ERP & Parent Management Training | First-line functional management for OCD, food restriction, and anxiety. | Weekly sessions tailored to acuity; systematic reduction of accommodation. | Adapt intensity during acute flares; monitor for caregiver burnout (Thienemann et al., 2017). |
Prong 1: Psychotropic | SSRIs (Fluoxetine, Sertraline) & Alpha-2 Agonists | Adjunct for severe OCD, anxiety, or hyperarousal. | Start at 25% to 50% standard dose; titrate slowly every 2+ weeks. | Monitor for behavioral activation, agitation, and QTc prolongation (Thienemann et al., 2017). |
Prong 2: Antimicrobial | Penicillin V, Amoxicillin-clavulanate, Azithromycin | Eradicate active/occult GAS or bacterial triggers. | 14-day therapeutic course at acute onset; prophylactic dosing if relapsing. | Monitor gastrointestinal tolerance and QTc interval with macrolides (Cooperstock et al., 2017). |
Prong 3: Anti-Inflammatory | NSAIDs (Ibuprofen, Naproxen) | Mild flares; early symptom management within 30 days of onset. | Standard pediatric weight-based dosing for 7 to 14 days. | Administer with food; monitor renal and gastrointestinal tolerance (Frankovich et al., 2017). |
Prong 3: Immuno-modulatory | Oral Corticosteroid Bursts (Prednisone) | Mild-to-moderate flares; rapid anti-inflammatory response. | 1 to 2 mg/kg/day for 5 days, or tapered over 3 to 4 weeks. | Monitor blood pressure, blood glucose, sleep disruption, and mood lability (Frankovich et al., 2017). |
Prong 3: Immuno-modulatory | High-Dose IVIG | Moderate-to-severe relapsing or refractory disease. | 1.5 to 2.0 g/kg total dose divided over 2 consecutive days. | Ensure adequate hydration; monitor for post-infusion headache, aseptic meningitis, and IgA levels (Frankovich et al., 2017). |
Prong 3: Immuno-modulatory | Therapeutic Plasma Exchange (TPE) | Extreme, life-threatening impairment (severe ARFID, catatonia). | 5 to 6 volume exchanges over 7 to 14 days in specialized setting. | Inpatient monitoring; central line infection, hypotension, and electrolyte shifts (Frankovich et al., 2017). |
A Father's Action Plan: School Accommodations, Advocacy, and Safeguarding
When PANDAS and PANS in children strike, fathers are often called upon to manage logistics, coordinate medical care, communicate with schools, and maintain stability at home. Having a clear action plan is essential for navigating these challenges effectively.
Building Effective School Accommodations (504 Plan / IEP)
Children undergoing acute flares frequently experience significant cognitive and academic setbacks. A child who was an A-student may suddenly fail simple math tests, be unable to hold a pencil due to fine motor decay, or miss school due to extreme urinary frequency. Fathers should work closely with school administrators to establish a 504 Plan or Individualized Education Program (IEP) incorporating specific accommodations:
Dysgraphia & Handwriting Deficits: Provide speech-to-text software, allow keyboarding, assign a class note-taker, offer enlarged grid paper for math, and waive penalties for messy handwriting or erasures.
Urinary Urgency: Issue a discrete, unrestricted bathroom pass that allows the child to leave the classroom immediately without asking permission or drawing attention from peers.
Separation Anxiety & Panic: Designate a safe room (such as the school nurse or counselor's office) and a trusted safe adult. Allow flexible morning arrival times during flares and permit parental presence during acute school re-entry.
Executive Dysfunction & Inattention: Reduce assignment length, grant 1.5x to 2.0x extended testing time, break complex multi-step instructions into written steps, and provide visual daily schedules.
Sensory Overload: Provide preferential seating away from noisy air conditioners or hallways, allow noise-canceling headphones, and grant passes for sensory breaks when needed.
Navigating Safeguarding and Fabricated or Induced Illness (FII) Allegations
One of the most distressing issues facing families managing PANDAS and PANS in children is the risk of misdirected safeguarding referrals or allegations of Fabricated or Induced Illness (FII), also known as Factitious Disorder Imposed on Another (PANS PANDAS UK, 2022).
Survey data indicate that approximately 20% of families managing PANS or PANDAS experience formal safeguarding referrals or FII accusations during their medical journey (PANS PANDAS UK, 2022; Clements & Aiello, 2021). This phenomenon occurs due to several clinical factors:
Symptom Masking: Children with PANS frequently mask their symptoms outside the home. A child may exert immense energy to hold their tics, anxiety, or compulsions in check while at school or during a brief medical appointment, only to collapse into severe rage or compulsions upon returning home. Uninformed educators or social workers may interpret this discrepancy as parental exaggeration or fabrication (PANS PANDAS UK, 2022).
Rapid Relapsing-Remitting Trajectory: The sudden appearance, disappearance, and shifting nature of PANS symptoms can confuse professionals accustomed to linear medical recovery, leading to mistaken suspicions of inconsistent parental reporting.
Seeking Multiple Medical Opinions: When local medical providers lack familiarity with PANS guidelines, desperate parents naturally seek out out-of-region specialists. Uninformed checklists may misinterpret this proactive advocacy as improper "doctor shopping" (Clements & Aiello, 2021).
Fathers can protect their families by keeping detailed medical binders that include objective physical documentation (handwriting samples, sleep logs, urine frequency charts, and throat culture reports), securing written diagnostic letters from treating pediatricians, and maintaining calm, collaborative communication with school and medical teams.
Practical Strategies for Fathers: Being the Anchor
Managing a child with PANDAS or PANS requires immense emotional resilience. As a father, your presence can serve as a vital stabilizing anchor for your child, your spouse, and your entire household.

Here are practical, actionable strategies for fathers:
Separate the Child from the Illness: During severe flares of rage or OCD, remind yourself that your child's brain is experiencing neuroinflammation. The aggression, screaming, or rejection is driven by an inflamed basal ganglia, not by malicious intent. Responding with calm, steady firmness rather than anger helps de-escalate acute flares.
Maintain a Detailed Symptom Log: Track symptom onset, severity, infectious exposures (strep exposures at school, family colds), antibiotic courses, and behavioral changes. Having clear, chronological data makes consultations with specialists significantly more productive.
Protect Your Marriage and Share the Burden: PANS and PANDAS introduce intense stress that can strain parental relationships. Divide caregiving duties equitably, ensure both parents get adequate sleep, and communicate openly about decisions regarding treatments and advocacy.
Support Healthy Siblings: Siblings of children with PANS often experience secondary stress or feel neglected when care concentratedly shifts to the unwell child. Reserve dedicated one-on-one time with healthy siblings to maintain their sense of security and connection.
Connect with Supportive Communities: Isolation breeds despair. Joining parent support organizations, such as Aspire (Alliance to Solve PANS and Immune-Related Encephalopathies) or the PANDAS Physicians Network (PPN), connects fathers with experienced parents and knowledgeable medical professionals.
A diagnosis of PANDAS or PANS in children presents families with an unexpected and challenging journey. Watching a child experience sudden neuropsychiatric changes is terrifying, but fathers do not have to navigate this path unprepared or helpless.
Understanding the underlying neuroimmunology, recognizing the full spectrum of warning signs, insisting on a thorough diagnostic evaluation, and pursuing an evidence-based, three-pronged treatment protocol can help children regain their health and return to their baseline. With calm determination, informed advocacy, and unwavering support, fathers can guide their children through the storm of neuroinflammation and toward lasting recovery.

Join the Fatherhood United Community
No father should have to navigate the sudden storm of PANDAS and PANS in isolation. Fatherhood United (www.fatherhoodunited.com) was created to ensure that fathers have a dedicated, supportive, and knowledgeable brotherhood when standing on the frontlines of their children's health and well-being.
When your family faces clinical ambiguity, sudden behavioral crises, or the exhausting strain of medical advocacy, you do not have to carry the burden alone.
Why Join Fatherhood United?
Peer-to-Peer Father Support: Connect directly with fellow dads who understand the daily realities of sudden-onset OCD, rage episodes, and complex neuroimmune care.
Practical Advocacy Toolkits: Access actionable guides, school accommodation templates (such as 504 and IEP plans), and strategies for navigating complex medical appointments with confidence.
Expert-Led Workshops & Discussions: Participate in live Q&A sessions, webinars, and panel discussions featuring pediatric specialists, neuroimmunology advocates, and veteran parent-carers.
A Safe Space for Dads: Share experiences, gain emotional clarity, and strengthen your leadership at home in a private, supportive community built by fathers, for fathers.
Take the next step in protecting your child and supporting your family. Visit www.fatherhoodunited.com today to join our community, access exclusive father-focused resources, and connect with dads who are walking the exact same path.
References
American Academy of Pediatrics. (2025). Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Clinical Report. Pediatrics, 155(1), e2024070334. doi: 10.1542/peds.2024-070334
Aspire. (2020). Diagnostic criteria for PANS & PANDAS: Current resources for general pediatricians. Alliance to Solve PANS & Immune-Related Encephalopathies.
Ben-Pazi, H., Stoner, J. A., & Cunningham, M. W. (2013). Dopamine receptor autoantibodies correlate with symptoms in Sydenham's chorea. PLoS ONE, 8(9), e73516. doi: 10.1371/journal.pone.0073516
Calaprice, D., Tona, J., & Murphy, T. K. (2018). Treatment of pediatric acute-onset neuropsychiatric disorder in a large survey population. Journal of Child and Adolescent Psychopharmacology, 28(2), 92–103. doi: 10.1089/cap.2017.0101
Cesaroni, C. A., Pisanò, G., Rizzi, S., Pantani, A., Frattini, D., & Fusco, C. (2026). PANDAS syndrome: A narrative review of the diagnostic conundrum in children with acute neuropsychiatric symptoms. International Journal of Molecular Sciences, 27(10), 4612. doi: 10.3390/ijms27104612
Chang, K., Frankovich, J., Cooperstock, M., Cunningham, M. W., Latimer, M. E., Murphy, T. K., Pasternack, M., Thienemann, M., Williams, K., Walter, J., & Swedo, S. E. (2015). Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference. Journal of Child and Adolescent Psychopharmacology, 25(1), 3–13. doi: 10.1089/cap.2014.0084
Clements, L., & Aiello, A. L. (2021). Institutionalising parent carer blame: The experiences of families with disabled children in their interactions with English local authority children's services departments. Cerebra & University of Leeds.
Cooperstock, M. S., Swedo, S. E., Pasternack, M. S., & Murphy, T. K. (2017). Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part III: Treatment and prevention of infections. Journal of Child and Adolescent Psychopharmacology, 27(7), 594–606. doi: 10.1089/cap.2016.0151
Cox, C. J., Sharma, M., Leckman, J. F., Zuccolo, J., Zuccolo, A., Kovoor, A., Swedo, S. E., & Cunningham, M. W. (2013). Brain human monoclonal autoantibody from Sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: Implications in human disease. Journal of Immunology, 191(11), 5524–5541. doi: 10.4049/jimmunol.1102592
Cox, C. J., Zuccolo, A. J., Edwards, E. V., Mascaro-Blanco, A., Alvarez, K., Stoner, J., Chang, K., & Cunningham, M. W. (2015). Antineuronal antibodies in a heterogeneous group of youth and young adults with tics and obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology, 25(1), 76–85. doi: 10.1089/cap.2014.0048
Cunningham, M. W. (2019). Molecular mimicry, autoimmunity, and infection: The cross-reactive antigens of group A streptococci and their sequelae. Microbiology Spectrum, 7(4), GPP3-0045-2018. doi: 10.1128/microbiolspec.GPP3-0045-2018
Dileepan, T., Smith, E. D., Knowland, D., Hsu, M., Platt, M., Bittner-Eddy, P., Cohen, B., Southern, P., Latimer, E., Harley, E., & Agalliu, D. (2016). Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells. Journal of Clinical Investigation, 126(1), 303–317. doi: 10.1172/JCI80792
Frankovich, J., Swedo, S., Murphy, T., Dale, R. C., Agalliu, D., Williams, K., Dalsgaard, S., & PANS Consortium. (2015). Clinical evaluation of pediatric acute-onset neuropsychiatric syndrome (PANS). Journal of Child and Adolescent Psychopharmacology, 25(1), 3–13.
Frankovich, J., Thienemann, M., Pearlman, J., Sullivan, K., Cooperstock, M. S., & PANS Consortium. (2017). Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part II: Use of immunomodulatory therapies. Journal of Child and Adolescent Psychopharmacology, 27(7), 574–593. doi: 10.1089/cap.2016.0148
Giedd, J. N., Rapoport, J. L., Garvey, M. A., Perlmutter, S., & Swedo, S. E. (2000). MRI assessment of children with obsessive-compulsive disorder or tics associated with streptococcal infection. American Journal of Psychiatry, 157(2), 281–283. doi: 10.1176/appi.ajp.157.2.281
Hesselmark, E., & Bejerot, S. (2017). Biomarkers for diagnosis of pediatric acute neuropsychiatric syndrome (PANS): Sensitivity and specificity of the Cunningham Panel. Journal of Neuroimmunology, 312, 31–37. doi: 10.1016/j.jneuroim.2017.09.002
International OCD Foundation. (2010). Sudden and severe onset OCD (PANS/PANDAS): Practical advice for practitioners and parents. International OCD Foundation.
Kaplan, E. L., Rothermel, C. D., & Johnson, D. R. (1998). Antistreptolysin O and anti-deoxyribonuclease B titers: Normal values for children ages 2 to 12 in the United States. Pediatrics, 101(1), 86–88. doi: 10.1542/peds.101.1.86
Kirvan, C. A., Swedo, S. E., Heuser, J. S., & Cunningham, M. W. (2003). Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nature Medicine, 9(7), 914–920. doi: 10.1038/nm892
Kirvan, C. A., Swedo, S. E., Snider, L. A., & Cunningham, M. W. (2006b). Antibody-mediated neuronal cell signaling in behavior and movement disorders. Journal of Neuroimmunology, 179(1-2), 173–179. doi: 10.1016/j.jneuroim.2006.06.017
Kirvan, C. A., Cox, C. J., Swedo, S. E., & Cunningham, M. W. (2007). Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. Journal of Immunology, 178(11), 7412–7421. doi: 10.4049/jimmunol.178.11.7412
Kovacevic, M., Grant, P., & Swedo, S. E. (2015). Use of intravenous immunoglobulin in the treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Journal of Child and Adolescent Psychopharmacology, 25(1), 65–69. doi: 10.1089/cap.2014.0067
Kumar, A., Williams, M. T., & Chugani, H. T. (2015). Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and Tourette syndrome: A positron emission tomographic (PET) study using 11C-[R]-PK11195. Journal of Child Neurology, 30(6), 749–756. doi: 10.1177/0883073814543303
Kurlan, R., & Kaplan, E. L. (2004). The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) etiology for tics and obsessive-compulsive symptoms: Hypothesis or entity? Practical considerations for the clinician. Pediatrics, 113(4), 883–886. doi: 10.1542/peds.113.4.883
Lim, E. C. N., Cheng, N. C. L., & Lim, C. E. D. (2026). Infection-associated pediatric acute-onset neuropsychiatric syndrome: A review of immunological mechanisms, clinical phenotypes, and therapeutic strategies. Infectious Disease Reports, 18(4), 69. doi: 10.3390/idr18040069
Mataix-Cols, D., Isomura, K., Pérez-Vigil, A., Chang, Z., Rück, C., Larsson, K. J., Leckman, J. F., Serlachius, E., Larsson, H., & Lichtenstein, P. (2015). Familial risks of Tourette syndrome and chronic tic disorders: A population-based cohort study. JAMA Psychiatry, 72(8), 787–793. doi: 10.1001/jamapsychiatry.2015.0627
Menendez, C. M., Zuccolo, J., Swedo, S. E., Reim, S., Richmand, B., Ben-Pazi, H., Kovoor, A., & Cunningham, M. W. (2024). Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders. JCI Insight, 9(18), e164762. doi: 10.1172/jci.insight.164762
PANDAS & PANS Treatment Guidelines (v1.6). (2021). The Children's e-Hospital. UK PANDAS Physicians Network.
PANS PANDAS UK. (2022). PANS, PANDAS & Fabricated or Induced Illness: Information for healthcare, social work and educational professionals. PANS PANDAS UK.
Perlmutter, S. J., Leitman, S. F., Garvey, M. A., Hamburger, S., Feldman, E., Leonard, H. L., & Swedo, S. E. (1999). Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet, 354(9185), 1153–1158. doi: 10.1016/S0140-6736(98)12297-3
Platt, M. P., Bolding, K. A., Wayne, C. R., Chaudhry, S., Cutforth, T., Franks, K. M., & Agalliu, D. (2020). Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis. Proceedings of the National Academy of Sciences, 117(12), 6708–6716. doi: 10.1073/pnas.1911097117
Shimasaki, C., Frye, R. E., Trifiletti, R., Cooperstock, M., Kaplan, G., Melamed, I., Greenberg, R., Katz, A., Fier, E., Kem, D., & Cunningham, M. W. (2020). Evaluation of the Cunningham Panel in PANDAS and PANS: Changes in antineuronal antibody titers parallel changes in patient symptoms. Journal of Neuroimmunology, 339, 577138. doi: 10.1016/j.jneuroim.2019.577138
Singer, H. S., Gilbert, D. L., Wolf, D. S., Mink, J. W., & Kurlan, R. (2012). Moving from PANDAS to CANS. Journal of Pediatrics, 160(5), 725–731. doi: 10.1016/j.jpeds.2011.11.040
Snider, L. A., Lougee, L., Slattery, M., Grant, P., & Swedo, S. E. (2005). Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biological Psychiatry, 57(7), 788–792. doi: 10.1016/j.biopsych.2004.12.035
Swedo, S. E., Leonard, H. L., Garvey, M., Mittleman, B., Allen, A. J., Perlmutter, S., Lougee, L., Dow, S., Zamkoff, J., & Dubbert, B. K. (1998). Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: Clinical description of the first 50 cases. American Journal of Psychiatry, 155(2), 264–271. doi: 10.1176/ajp.155.2.264
Swedo, S. E., Leckman, J. F., & Rose, N. R. (2012). From research subgroup to clinical syndrome: Modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome). Pediatric Therapeutics, 2(2), 113. doi: 10.4172/2161-0665.1000113
Thienemann, M., Murphy, T., Leckman, J. F., Shaw, R., Williams, K., Kapphahn, C., Frankovich, J., Geller, D., Bernstein, G., Chang, K., Elia, J., & Swedo, S. E. (2017). Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part I: Psychiatric and behavioral interventions. Journal of Child and Adolescent Psychopharmacology, 27(7), 566–573. doi: 10.1089/cap.2016.0145
Toufexis, M. D., Hommer, R., Gerardi, D. M., Grant, P., Rothschild, L., D'Souza, P., Kasalter, M., & Swedo, S. E. (2015). Disordered eating and food restrictions in children with PANS/PANDAS. Journal of Child and Adolescent Psychopharmacology, 25(1), 48–56. doi: 10.1089/cap.2014.0063
Wayne, C. R., Akcan, U., Faust, T. E., Durán-Laforet, V., & Agalliu, D. (2026). Th17 effector cytokines induce shared and distinct microglial and endothelial cell responses in a mouse model for post-streptococcal encephalitis. ResearchGate / Journal of Neuroinflammation.
Xu, J., Liu, R. J., Fahey, S., Frick, L., Leckman, J., Vaccarino, F., & Swedo, S. (2021). Antibodies from children with PANDAS bind specifically to striatal cholinergic interneurons and alter their activity. American Journal of Psychiatry, 178(1), 48–64. doi: 10.1176/appi.ajp.2020.19070698
Xu, J., Frankovich, J., Liu, R. J., Thienemann, M., Silverman, M., Farhadian, B., Willett, T., Manko, C., Columbo, L., Leibold, C., & Swedo, S. E. (2024). Elevated antibody binding to striatal cholinergic interneurons in patients with pediatric acute-onset neuropsychiatric syndrome. Brain, Behavior, and Immunity, 122, 241–255. doi: 10.1016/j.bbi.2024.07.044



Comments